September 13, 2013 11:31 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a report published Friday, D.A. Davidson analyst Jeff Rulis upgraded the rating on
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Umpqua Holdings Corp. (NASDAQ: UMPQ) from Neutral to Buy, and raised the price target from $17.00 to $20.00.In the report, D.A. Davidson noted, “Sterling shareholders will receive 1.671 shares of Umpqua common stock in addition to $2.18 cash, which equates to $30.52 per share or 1.67x Sterling's TBV (93% stock / 7% cash). The deal is expected to close in 1H'14. The combined entity, which will operate under the Umpqua brand, will hold $22 billion in assets, $15 billion in loans, and $16 billion in deposits with 394 branches across 5 states. The acquisition would position UMPQ as a premier community bank, holding a top 3 ranking among locally headquartered banks by deposit market share in 10 out of 11 primary markets. The pro forma loan book will be CRE based (43%) with a higher emphasis in multifamily (16% pro-forma vs. 5% UMPQ) and 1-4 family loans (14% pro-forma vs. 10% UMPQ). Management believes this to be a strategic acquisition that leverages the UMPQ brand and fortifies an expanded footprint.”Umpqua Holdings Corp. closed on Thursday at $16.20.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.